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Identification of peptide sequences that
potentially trigger HLA-A2.1-restricted cytotoxic
T lymphocytes*
We used the human processing defective cell line 174CEM.T2 (T2) to identify
potential cytotoxicT lymphocyte (CTL) epitopes of human proteins. Exogenous-
ly added peptides can increase the number of properly folded HLA-A2.1
molecules on the cell surface of T2 cells, as shown by immunofluorescence
measurements using the mouse monoclonal antibody BB7.2 (anti-HLA-A2.1)
and fluorescein isothiocyanate-Iabeled goat anti-mouse F(ab')2 antibody. The
peptides were selected on the basis of a computer score derived from the recently
described HLA-A2.1 specific motif. Analysis of the influenza matrix protein
showed that 15 out of 35 high-scoring peptides up-regulate the expression of
HLA-A2.1 molecules on the T2 cell surface. The combination of the computer
scoring program and an immunofluorescence-based peptide binding assay allows
rapid detection of potential CTL target peptides.
1 Introduction
The MHC gene products associate with peptides and are
recognized by cytotoxicT lymphocytes (CTL) [1]. Class I
molecules are membrane heterodimers composed of a
45-kDa heavy (H) chain noncovalentiy associated with an
invariant light chain, (Ji-microglobulin (p2m).The H chain
has three extracellular domains: al, a2 and cc3. The
amino-terminal al and a2 domains interact with each other
to form a peptide-binding groove, while the a3 domain
adjacent to the plasma membrane directly contacts fern [2j.
The H chains associate with P2m shortly after synthesis in
the endoplasmic reticulum (ER) [3]. Assembly of the H
chain with p^m and peptide is required for conformational
stability and presentation at the cell surface of peptides
[4-7]. Proteins present in the cytosol appear to be cleaved
into fragments of 8-11 amino acids [8, 9]. The class 1
molecules are, on their way to the cell surface, loaded with
peptide in or between the ER and the Golgi complex
[10-13].
Recent studies have identified mouse and human cell lines,
designated RMA-S [4], 721.174 [14] and 174CEM.T2 (T2)
[15], which produce abundant cytoplasmic H chains and
p^m, but present low amounts of surface MHC molecules.
These so-called processing-defective cell lines are unable to
present endogenously synthesized peptides to CTL [4,16].
The processing defect in the T2 cell line is due to a
homozygous deletion of the MHC class II region located on
chromosome 6 including theTAPl and TAP2 (transporters
associated with antigen processing) genes which encode the
transporter proteins [17].The HLA-A2.1 molecules are the
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only HLA molecules present, at low density, on the cell
surface of the T2 cell line and are at least partially occupied
by peptides derived from the signal peptide domains of
normal cellular proteins (IP-30, calreticuline) [18-20].
The 721.174 cells present exogenously added peptides
which can bind to HLA-A2.1 at relatively high levels
despite the relatively low levels of steady state expression
of cell surface HLA-A2.1 molecules [21]. We used the T2
line, a cell line with the same processing defect as 721.174
cells, to identify peptide binding to HLA-A2.1 by measur-
ing the HLA-A2.1 cell surface expression. The peptides
used in our tests were selected using a computer scoring
program derived from the HLA-A2.1 peptide motif
([22];*). We chose to study the influenza matrix protein
because a previously described influenza matrix-specific
HLA-A2.1-restricted CTL clone recognizes a defined
influenza matrix epitope [23. 24] which we expected to
detect in our test system.
2 Materials and methods
2.1 Scoring system
Sequencing of peptides eluted from purified HLA-A2.1
molecules revealed an HLA-A2.1 allele-specific peptide
motif [20, 22]. It includes peptides with a length of nine
amino acids with two anchor residues, a leucine, isoleucine
or methionine at position 2 and a hydrophobic aliphatic
residue at position 9, the C-terminal residue. The term
anchor residue was used for the positions revealing a strong
signal for only one amino acid or a few amino acids with
closely related side chains. Furthermore, "strong and
weak" amino acids are described in the different positions.
We developed our own computer scoring program deduced
from the HLA-A2. l peptide motif .We scored six points for
an anchor residue, four points for a strong and two points
for a weak residue .The score for a given peptide is obtained
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by multiplication of the scores for each amino acid position.
In this way the maximum score for a peptide of a length of
nine amino acids is 36 864 points (62 points x 43 points X 24
points). Peptides lacking anchor residues at position 2 and
at the C-terminal end were discarded. Peptides longer than
nine amino acids can also bind to MHC molecules depend-
ing on the sequence [25]. Therefore, the computer program
also scores for peptides with a second anchor residue at
position 10 or 11.
2.2 Peptide binding study
Peptides were synthesized by solid-phase strategies on an
automated multiple peptide synthesizer (Abimed AMS
422) using Fmoc chemistry. The purity of the peptides was
determined by reverse-phase HPLC. Peptides were dis-
solved in DMSO (final DMSO concentration 0.25%) and
diluted in 0.9% NaCl to apeptide concentration of 2 nig/ml
and stored at - 20 °C. The T2 cell line, a gift from Dr. P.
Cresswell (Dept. of Immunology, Yale University, New
Haven, CT), was cultured in Iscove's modified Dulbecco's
medium (IMDM) (Biochrom KG, Seromed Berlin, FRG)
with 2mM glutamine, 100 lU/ml penicillin, 100 ug/ml
kanamycin and 10% fetal calf serum (PCS, Hyclone
Laboratories Inc. Logan, UT). The T2 cells were washed
twice in serum-free culture medium. Cells (80000) in 40 uj
serum-free medium were put into a V-bottom 96-well plate
together with 10 ul of the peptide dilution at different
concentrations or 10 u.1 0.9% NaCl, and incubated over-
night at 37 °C, 5% CO2 in humidified air. The cells were
washed once with cold (4°C) "PBA" (0.9% NaCl, 0.5%
BSA, 0.02% NaNj) and stained by indirect immunofluor-
escence. The first antibody BB7.2 (HLA-A2.1-specific
monoclonal antibody) was added in a saturating amount
and incubated for 30 min at 4 °C. After two washing steps
with cold PBA, FITC-labeled F(ab')2 fragments of goat
anti-mouse IgG (Tago Inc. Burlinger, CA) in a dilution of
1:40 were added as the second antibody and incubated for
another 30 min at 4°C. The cells were washed once and
fluorescence was measured at 488 nm on a FACScan flow
cytometer (Becton Dickinson, Franklin Lakes, NJ).
The fluorescence ratio (FR) was calculated with the
formula: mean fluorescence experimental sample / mean
fluorescence background.
Human p2m (Sigma, St. Louis, MO) was dissolved in
serum-free IMDM and stored at — 20 °C at a concentration
of 1 mg/ml. Human p2ni was used during the incubation
period of the T2 cells with the peptide.
2.3 Competition cytotoxictty assay
The influenza matrix-specific HLA-A2.1-restricted CTL
clone was a generous gift from Dr. H. Spits (DNAX, Palo
Alto, CA). The CTL clone was grown on HLA-A2.1-
positive EB V-transformed B cell lines irradiated with 30 Gy
in RPMI (Gibco Paisley, Scotland) with 2 mM glutamine,
100 lU/ml penicillin, 100 ug/ml kanamycin and 10% FCS
(Hyclone Laboratories). In the competition cytotoxicity
assay 2000 51Cr-labeled T2 cells (25 \i\ complete IMDM
medium/well) were incubated with 5 u.1 of the influenza
CTL epitope (0.5 ug/ml, final concentration) in the pre-
sence or absence of 5 ul of one of the competitor synthetic
peptides (20 ug/ml, final concentration) in a U-bottom
96-well plate. After 20 min of incubation the influenza-
specific CTL clone was added in a volume of 25 u.1 of
complete IMDM medium at an effector to target ratio of
5 :1 for an additional 4 h. The percentage 51Cr release was
calculated with the formula: [(cpm experimental well -
background 51Cr release) / (maximum 51Cr release -
background 51Cr release)] x 100.
The background was always less than 25% of maximal
release. The percentage blocking was calculated with the
formula: [1 - (% 51Cr release of target cells incubated with
epitope and competitor peptide / % 51Cr release of target
cells incubated with epitope)] x 100.
3 Results
3.1 Scoring system
Fig. 1 illustrates the score distribution for peptides of the
influenza matrix protein using a computer scoring program,
the highest score was 1152 points. Peptides with anchor
residues at position 2 and the C-terminal end were selected
for synthesis (Tables 1 and 2). Eighteen peptides chosen
randomly i. e. not according to the selection rules, were used
as control peptides (Table 3). The influenza matrix epitope
recognized by a HLA-A2.1-restricted CTL is one of the
selected peptides with a high score (seq. no. 58-66; 576
points, Table 1). The computer scoring program revealed
only 35 peptides (8% of the total number, Table 1) with a
relatively high score of 144 points or higher, which makes it
a useful first step in finding potential CTL epitopes.
Peptides with anchor residues at position 2 and the
C-terminal end with a score lower than 144 points are
depicted in Table 2.
3.2 Peptide binding assay
Out of 35 high-scoring influenza matrix peptides, including
the nonamer 58-66,15 up-regulated the HLA-A2.1 mole-
24 32 36 48 64 72 36 1
score distribution
Figure 1. The score distribution for peptides of the influenza
matrix protein using the computer scoring program. The maximum
score for a peptide is 36864 points (62 points x 43 points x 24
points). Peptides with an anchor residue at position 2 and the
C-terminal end were used in our experiments together with 18
control peptides.
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Table 1. The Influenza matrix peptides with a high scorea:











































































I I P S G P L K A
I I P S C P L K A E I
V L M E W L K T R P I
L L T E V E T Y V
L L T E V E T Y V L
I L S P L T K G Ï
I L S P L T K G I L
P L T K G I L G F V
G I L G F V F T L
G I L G F V F T I T V
K L Y R K L K R E I
E 1 T F H G A K E I
S t L T E V E T Ï V
S L L T E V E T V V L
P I L S P L T K G I
P I L S P L T K G I L
R H G A V T T E V
R H G A V T T E V A
R I G T H P S S S A
V L D I I P S G P L
P L K A E I A Q R L
E I A Q R L E D V
E I A Q R L E D V F A
I L G F V F T L T V
K I K R E I T F H G A
L t Y N R M G A V
G L V C A T C E Q I A
G L V C A T C E Q I
Q H V T T T N P L
Q M V T T T N P L I
L I E H E N R M V
L I R H E H R M V L
L I R H E K R M V L A
Q M A G S S E Q A


























































a) The sequence number fSeq. nr.) of the first
amino acid is shown. The peptides are ranked
according to their computer score.The fluores-
cence ratio (final peptide concentration in the
binding assay was 100 (ig/ml). % blocking of
lysis using an E/Tof 5 :1.T2 was the target cell
line. The asterisk indicates the binding pep-
tides. For conditions of blocking see
Sect. 2.3.
Table 2. The Influenza matrix peptides with a low score"'
180 24
pepti F.R.
cule cell surface expression on theT2 cell line, while none of
the low-scoring or control peptides did so (cut off > 1.5)
(Tables 1-3 column FR). The FACScan results shown in
Tables 1-3 were highly reproducible. The FACScan proce-





























































































S G P L
L K T R
L K T R
R P I L
S Y S A
S Y S A
S A G A
S A G A
C M G L
I Y N R
I Y N R
N R H G
K R H G
H E N R
H E N R
H E N S
Y Q K R
Y Q K S
L M E W
P S E R
R R F V
A S T A





























































































L K A E I A Q R L
V F A G K N T D L
V L M E W L K T R
K T R P I L S P L
L I K G I L G F V
L G F V F T L T V
Q R R R F V S N A
G D P H N M D K A
N H H D K A V K L
K A V K L Y R K L
K L Y R K L K R E
L Y R K L K R E I
I T F H G A K E I
I R H E N R M V L
M V L A S T A K A
G S S E Q A A E A
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a) See footnote to Table 1.
232 D L L E N L Q A Y
b) The peptides are ranked according to their sequence
number.
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To determine if peptides which up-regulate the HLA-A2.1
molecule actually bind to the HLA-A2.1 molecule we
tested 11 binding peptides and 26 non-binding peptides for
competition in a cytotoxicity assay. We expected those
which up-regulate the HLA-A2.1 molecule on theT2 cell
surface to block lysis of an HLA-A2.1-restricted CTL clone
specific for the influenza matrix protein. The results in the
last column of Tables 1 and 3 show that peptides which
up-regulate HLA-A2.1 block the lysis of the CTL clone,
except the peptides 58-66 and 59-68 which are recognized
by the CTL clone (cut off £50% blocking).
3.3 Effect of human IV-m
The detection threshold of HLA-A2.1 up-regulation lies at
a concentration of 25 to 50 ng/ml peptide without p^m
(Fig. 2). The detection level of HLA-A2.1 up-regulation is
at a concentration of 6.25 to 12.5 ug/ml peptide with p^m
(Fig. 2). The addition of free human (32m increases the
overall HLA-A2.1 cell surface expression compared to
tests in which no fcm was added (Fig. 2). The sensitivity of
the peptide binding assay is not further enhanced by the
addition of higher concentrations (> 20 ug/ml) of p^m (data
not shown). We conclude that human p^m increases the
sensitivity of our peptide binding assay without affecting
background binding. The optimal final concentration of
human P2tn is 15 ug/ml.
mean fluorescence
4 Discussion
Peptides which bind to HLA-A2.1, if immunoreactive,
might be suitable for use as vaccine components to prevent
the outgrowth of tumors or pathogens which express those
peptides in the context of HLA-A2.1. A number of recent
studies in mice have indicated the feasibility of this
approach [26-28j. Preventive peptide vaccination using a
T cell epitope of the lymphocytic choriomeningitis virus
(LCMV)-NP can reduce the virus titer when mice are
infected with LCMV [26]. Immunization of mice with a
virus-specific CTL epitope derived from the Sendai virus
protects them from a lethal infection [27]. Immunization
with synthetic peptides derived from a tumor-inducing
virus reduces the growth of these tumors [28].
The therapeutic value of CTL has been reviewed [29, 30].
Binding peptides might be used to induce a primary CTL
response using theT2 cell line loaded with a binding peptide
as an antigen-presenting cell. A similar approach has been
reported for the mouse system [31]. One of the problems
might be that in vitro primed CTL stimulated with peptides
might not always recognize endogenously processed antig-
ens, in contrast to their recognition of cells sensitized with
the target antigen [32]. Harty and Bevan overcame this
problem by in vitro restimulation of spleen cells of mice
immunized with a synthetic peptide with cells transfected
with the gene encoding the epitope [33]. Using this method,
high-affinity CTL clones were generated, instead of CTL
clones which only recognize peptide-loaded target cells.
Human fam is required for the post-translational process-
ing and transport of all HLA-A, -B and C gene products to
the cell surface [34, 35]. The effect of fcm in our peptide
control 5 to 15
microgram/ml B2m
-<— 100 -*- 50 -a- 25 -*- 12.5 -»- 8.25 -»- 0
Figure 2. Effect of fS2m on the up-regulation of HLA-A2.1
molecules on the T2 cell surface. pVn was used at four different
concentrations (5-10-15-20 ug/ml). No p2m was used in the control
test. The peptide concentrations were 100; 50; 25; 12.5; 6.25;
0 [ig/ml (several binding peptides were used).
binding assay can be explained in different ways. First, the
addition of human p2m might increase the number of
peptide binding sites on the cell surface, for example by
rescue of free heavy chains from dissociation. In that case
the HLA molecules remain available for peptide acquisi-
tion. Indeed, Boyd et al. showed that the number of high
affinity binding sites increased when p^rn was used together
with purified soluble analogues of MHC molecules [36].
Second, p^m may selectively bind to the heavy chain which
is already stabilized by a binding peptide [37]. Finally,
Otten et al. reported that when the fern-heavy chain
complex begins to dissociate it would become more acces-
sible to peptide binding [38]. The number of HLA-A2.1
molecules on the cell surface of the T2 cell line does not
increase when (32m is used (maximum fJ3m concentration 20
u.g/ml) without a peptide or a non-binding peptide (see
Fig. 2 at peptide concentration of 0 ug/ml).
One may expect that further refinements of the HLA-A2.1
peptide motif will be possible in the near future. The
peptide motif does not take into account that flanking
amino acids of the presented peptide might influence the
processing and presentation of peptides [39]. Therefore,
not all binding peptides are likely to be processed in vivo.
On the other hand most naturally processed self peptides
and viral epitopes conform to the motif.
Peptide sequences that potentially trigger HLA-A2.1-
restricted CTL can be easily detected using our test system.
Our computer scoring program in combination with the
peptide binding assay can be used for other HLA mole-
cules. For that purpose one requires a peptide motif, T2
cells transfected with the specific HLA-allele and a mono-
clonal antibody specific for that HLA molecule. The
HLA-A2.1 molecule is present in 40% of the Western
European Caucasoid population. Thus, in principle those
individuals could benefit from treatment with tumor-
specific CTL or tumor-associated peptides.
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manuscript.
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